University of Oslo

"Double Life" of Key Immune Protein Reveals New Strategies for Treating Cancer and Autoimmune Diseases

Retrieved on: 
Vendredi, mars 8, 2024
Bangladesh Technical Education Board, University of Oslo, Cancer, University, The central science, Immune system, Research, Doctor of Philosophy, Science Immunology, National Institutes of Health, MD, Moses Austin, Neoplasm, Inflammation, Wang, Wellcome Trust, Rheumatology, Lupus, PD-1, Bristol Myers Squibb, Howard Hughes Medical Institute, Biochemistry, NYU, Autoimmunity, Perlmutter, Rheumatoid arthritis, Pathology, Ligand, Pharmacology, NYU Langone Health, Patient, Hanmi Pharmaceutical, Internal medicine, Biomedical sciences, Funding of science, Columbia University, Mouse, Vaccine

The same findings also support experimental treatment strategies for autoimmune diseases, in which the immune system attacks the body, because stimulating the action of PD-1, as opposed to restricting it, can potentially block an overactive immune response.

Key Points: 
  • The same findings also support experimental treatment strategies for autoimmune diseases, in which the immune system attacks the body, because stimulating the action of PD-1, as opposed to restricting it, can potentially block an overactive immune response.
  • The study results revolve around the body's immune system, which is primed to attack virally infected and cancerous cells while leaving normal cells alone.
  • The immune system recognizes tumors as abnormal, but cancer cells can hijack checkpoints to turn off immune responses.
  • At the same time, PD-1 signaling is slowed in autoimmune diseases like rheumatoid arthritis, lupus, and type 1 diabetes, such that the action of unchecked immune cells creates inflammation that can damage tissues.

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

Retrieved on: 
Mercredi, novembre 15, 2023
Science, Other Science, Research, Public Relations, Investor Relations, General Health, Health, Communications, Clinical Trials, De Veenhuis, Movement disorder, DNA, CERP, Oculomotor apraxia, ChromaDex, Liver, Clinical trial, Cerebellar degeneration, Patient, Multimedia, Nicotinamide adenine dinucleotide, Immunodeficiency, Movement, DNA repair, Cerebellar ataxia, Cognition, Eye, University, Trial of the century, University of Oslo, Biomarker, NAD, Medical device, Ataxia–telangiectasia

The promising results demonstrate that long-term supplementation with Niagen NR effectively increased whole blood NAD+ levels up to fourfold, improved coordination, and enhanced eye movement while maintaining biomarkers of stable liver and kidney function in Ataxia Telangiectasia (AT) patients.

Key Points: 
  • The promising results demonstrate that long-term supplementation with Niagen NR effectively increased whole blood NAD+ levels up to fourfold, improved coordination, and enhanced eye movement while maintaining biomarkers of stable liver and kidney function in Ataxia Telangiectasia (AT) patients.
  • AT is a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition.
  • View the full release here: https://www.businesswire.com/news/home/20231115900463/en/
    Newly published phase II clinical study demonstrates that supplementation with Niagen, patented nicotinamide riboside (NR), elevates NAD+ up to fourfold, improving motor coordination and eye movement in Ataxia Telangiectasia (AT) patients (Graphic: Business Wire)
    Building on a growing body of research, this is the second published study ( Veenhuis et al.
  • This growing body of research is promising as it demonstrates that NR supplementation may be a potential therapeutic strategy for AT patients.”

VIKING RETURNS TO ANTARCTICA FOR THIRD SEASON

Retrieved on: 
Mardi, novembre 28, 2023
Alfresco, Austral, University, Ship, Engineering, Scott Polar Research Institute, Science, The Shelter, Element, Energy efficiency, The Living Room, Finse, Interview, Travel, Suite, Safety, Paper, Cornell Lab of Ornithology, Heart, Norwegian Polar Institute, Viking Octantis, Letter, Nobel Peace Prize, Shelter, Living room, 2018 Nobel Peace Prize, Observation, Longitudinal, Laboratory, White, Exploration, Partnership, Life, Library, Polar Research, Elbow, Research, Panama Canal, University of Oslo, Restaurant, Spacecraft, Antarctic Peninsula, NOAA, University of Cambridge, Environment, Heywood Hill, Whaling, Shipbuilding, Nightclub, Arctic, Vikings, Antarctica

LOS ANGELES, Nov. 28, 2023 /PRNewswire/ -- Viking® (www.viking.com) is celebrating the start of its third expedition season in Antarctica, as the Viking Octantis® and her identical sister ship, the Viking Polaris® have arrived again in the region. Both ships will spend the Austral summer in Antarctica, before returning to North America's Great Lakes for voyages throughout the spring, summer and early fall.

Key Points: 
  • LOS ANGELES, Nov. 28, 2023 /PRNewswire/ -- Viking® ( www.viking.com ) is celebrating the start of its third expedition season in Antarctica, as the Viking Octantis ® and her identical sister ship, the Viking Polaris ® have arrived again in the region.
  • To meet strong demand for Antarctica voyages, Viking has also announced that the 2025-2026 season is now open for booking, including a new 87-day expedition, From the Arctic to Antarctica , sailing from Nuuk, Greenland to Ushuaia, Argentina.
  • "As we welcome guests back for a third season in Antarctica, we are pleased to introduce even more opportunities for the curious traveler to experience this phenomenal region in Viking comfort," said Torstein Hagen, Chairman of Viking.
  • On my own trip to Antarctica, I witnessed firsthand the incredible scenery and wildlife this fascinating continent has to offer.

Trailblazing the Future of Healthy Aging Science: Timeline® Hosts the First Global Urolithin A Summit With a Full-day Virtual Experience

Retrieved on: 
Vendredi, novembre 3, 2023
Other Health, Other Communications, Diabetes, Health, General Health, Oncology, Communications, Other Science, Research, Fitness & Nutrition, Science, Ageing, National University of Singapore, Buck Institute for Research on Aging, Doctor of Philosophy, Princeton University, University of Rhode Island, Urolithin A, National university, University, University of Oslo, Longevity, Nursing, Timeline, MD

On November 7th, the first global Urolithin A Scientific Summit, brought to the world stage by Timeline , is set to present paradigm-shifting research in the field of longevity.

Key Points: 
  • On November 7th, the first global Urolithin A Scientific Summit, brought to the world stage by Timeline , is set to present paradigm-shifting research in the field of longevity.
  • Led by experts in the scientific community, the virtual summit, open to the general public, practitioners, and scientists, will highlight the latest research in aging, particularly focusing on Urolithin A—a breakthrough postbiotic natural molecule with a meaningful impact on health.
  • Urolithin A stands at the forefront of healthy aging with its unique potential to target several of the most important hallmarks of aging.
  • “Timeline has always been at the cutting edge and this event marks a significant milestone in our journey of raising the bar in longevity, nutrition and skin health science.”

Exploration at the 5th NYO3 NO-AGE/AD Meeting and the First Launch of New Anti-Aging Nutrition Co-Developed by NYO3 and NO-AGE

Retrieved on: 
Mardi, septembre 26, 2023
Alternative Medicine, Health, General Health, Research, Science, Vitamins, Supplements, Biotechnology, University, DHA, Counselor, Mission, Ageing, Phospholipid, University of Oslo, EPA, Regeneration, Diplomatic mission, United Kingdom, Choline, Education, Dietary supplement

On September 18-19 (Norwegian time), the 5th NYO3 NO-AGE/AD Meeting was successfully held at the University of Oslo, Norway.

Key Points: 
  • On September 18-19 (Norwegian time), the 5th NYO3 NO-AGE/AD Meeting was successfully held at the University of Oslo, Norway.
  • With deep awareness of the importance of anti-aging for human health, Norwegian high-end dietary supplement brand NYO3 shared the latest research on krill oil, an anti-aging nutrition, about its promotion of neuronal health by inhibiting senescence markers at the meeting.
  • NYO3 brought a new anti-aging nutrition into view.
  • The 5th NYO3 NO-AGE/AD Meeting has built a pioneering force in the field of anti-aging and health nutrition, and also provided a new reflection of the world’s cutting-edge scientific research achievements on promoting industry development.

Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer

Retrieved on: 
Lundi, septembre 11, 2023
Biotechnology, Pharmaceutical, Health, Employment, University, RSU, Information technology, MBA, University of Oslo, Cerus Corporation, Patient, Harvard Business School, J.P. Morgan & Co., Professional Football Compensation Committee, Pleasure, CFO, Growth, Therapy, Compensated emancipation, J. P. Morgan, Disease, Spiroplasma mirum, Chinook

“Eric is an accomplished CFO bringing an outstanding track record in driving financial performance, business development, and operations management,” said Chris Peetz, president and chief executive officer at Mirum.

Key Points: 
  • “Eric is an accomplished CFO bringing an outstanding track record in driving financial performance, business development, and operations management,” said Chris Peetz, president and chief executive officer at Mirum.
  • He comes to Mirum from Chinook Therapeutics, Inc., where he served as CFO overseeing financial reporting, planning and budgeting, internal controls, investor relations, facilities, and information technology functions.
  • Prior to Chinook, he served as CFO at Aimmune Therapeutics, Inc. Before Aimmune, Eric worked at Sunesis Pharmaceuticals, Inc., IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc., and Age Wave, LLC.
  • “Mirum is an exciting company that has achieved significant success in a short period of time,” said Mr. Bjerkholt.

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

Retrieved on: 
Vendredi, juin 16, 2023
Health, Hospitals, Other Health, General Health, Pharmaceutical, Vitamins, Supplements, Biotechnology, University of Helsinki, Science, Human, Cell Metabolism, University, PD, Heart failure, Metabolism, CERP, Science Advances, NR, Placebo, LVEF, Spinal cord, Research fellow, Clinical trial, Ageing, NAD, University of Oslo, Philip Morris External Research Program, ChromaDex, Research, Brain, Inflammation, Affiliation, Mitochondrion, DSM-IV codes, University of Washington School of Medicine, Trial of the century, Associate, Haukeland University Hospital, University of Bergen, City, Publication, Parkinson's disease, Patient, Division, Heart, University of Copenhagen Faculty of Health and Medical Sciences, University of Oulu, Diabetes, Safety, Copenhagen, Dietary supplement, Pharmaceutical industry, Medical device, Nicotinamide riboside, Cardiology

On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).

Key Points: 
  • On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).
  • On behalf of the ChromaDex family, we are thrilled to commemorate our ChromaDex External Research Program as it celebrates a decade of setting the industry standard for excellence in collaborative research,” said Rob Fried, the CEO of ChromaDex.
  • This approach fosters great trust in the research, as often there is skepticism around industry-funded research in the dietary supplement industry.
  • Today, this unique, industry-leading program has research agreements with over 200 institutions in 31 countries, representing over $95 million in estimated total research value.

NEW NUTRITION BEYOND LIMITS | The GLOBAL BRAND CELEBRATION of NYO3 in Oslo, Norway

Retrieved on: 
Jeudi, mai 25, 2023
Biotechnology, Vitamins, Supplements, Health, Fitness & Nutrition, Pharmaceutical, Heart, Aker BioMarine, Organization, University of Oslo, Gold, AWR, Knowledge, Dietary supplement, Innovation Norway

On May 15th (Norwegian Time), high-end dietary supplement brand NYO3 held its GLOBAL BRAND CELEBRATION in Oslo.

Key Points: 
  • On May 15th (Norwegian Time), high-end dietary supplement brand NYO3 held its GLOBAL BRAND CELEBRATION in Oslo.
  • With the slogan of "NEW NUTRITION BEYOND LIMITS", it vigorously released a new product of golden ultra-boost krill oil, announced the global strategic layout of NYO3, and jointly initiated the AWR global public welfare action with its strategic partner Aker BioMarine.
  • This event also invited organizations such as the Innovation Norway, NO-AGE, UiO, ORIVO, where offered an international nutrition knowledge exchange feast to meet the global users’ need of upgraded high-quality health products.
  • NYO3 and its strategic partner Aker BioMarine jointly unveiled a high-end new product - NYO3 Gold ultra-boost Krill Oil, LYSOVETA LPC-EPA/DHA, and Krill Protein Marine Protein Peptide at the event.

VIKING ANNOUNCES NEW EXPEDITION VOYAGES IN THE ARCTIC

Retrieved on: 
Jeudi, mai 25, 2023
Spacecraft, The Shelter, Elbow, Travel, University, Shelter, National Oceanic and Atmospheric Administration, Great Lakes, University of Cambridge, Geology, NOAA, Alfresco, Hagen, Exploration, Observation, Cornell Lab of Ornithology, Environment, Ilulissat Icefjord, Heart, Science, Panama Canal, Viking Octantis, Cambridge University Museum of Zoology, Research, Element, Suite, High Arctic relocation, Energy efficiency, Safety, Scott Polar Research Institute, The Living Room, History, Ship, Engineering, 2018 Nobel Peace Prize, Restaurant, Bird, Living room, Partnership, Laboratory, Heywood Hill, Nature, Library, University of Oslo, Nobel Peace Prize, Whaling, Shipbuilding, Nightclub, Vikings, Inuit, Arctic, Northwest Passage

LOS ANGELES, May 25, 2023 /PRNewswire/ -- Viking® (www.viking.com) today announced three new summer season expedition voyages in the Arctic. Debuting in July 2025, the new itineraries, which range from 13 to 27 days, explore the polar north in Canada and Greenland, with two of the three voyages visiting the Canadian High Arctic.

Key Points: 
  • LOS ANGELES, May 25, 2023 /PRNewswire/ -- Viking® ( www.viking.com ) today announced three new summer season expedition voyages in the Arctic.
  • "Our guests are curious travelers who are eager to explore new and different regions of the world, in Viking comfort," said Torstein Hagen, Chairman of Viking.
  • Join Viking on a fascinating voyage exploring the Canadian High Arctic to undiscovered territories beneath the skies of the midnight sun.
  • Enrichment On Board and On Shore: Viking has created the world's leading scientific enrichment environment in an expedition setting.

TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting

Retrieved on: 
Lundi, mai 1, 2023
Prostate cancer, Comparison, McCormick Place, BPH, AUA, LUTS, Clinical trial, Cancer, American Urological Association, Prostate, Patient, United States Army Medical Corps, Annual general meeting, Fellow, Pivotal, TSX, University of Oslo, Prostatectomy, Erectile dysfunction, Safety, Level 1, Johns Hopkins School of Medicine, Pharmaceutical industry, Medical imaging

TORONTO, May 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the presentation of four studies of the Transurethral Ultrasound Ablation (“TULSA”) procedure at the American Urological Association (“AUA”) 2023 Annual Meeting, which took place from April 28 - May 1, 2023 at McCormick Place in Chicago, Illinois.

Key Points: 
  • The data demonstrate that both oncological control and functional outcomes are durable to four years after treatment with TULSA.
  • Urinary function was durable over the four-year follow-up period, with 99% of patients preserving urinary continence (≤1 pad/day) and 94% remaining completely pad-free.
  • At follow-up, oncological success was 88%, with 85% of men with LUTS before treatment experiencing relief after treatment with TULSA.
  • There were two Grade 4 complications - one after HIFU ablation and one after RALP - but none after TULSA.